Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy

Neurogen Brain and Spine Institute1 site in 1 countryAugust 2013

ConditionsCerebral Palsy

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Cerebral Palsy
Sponsor: Neurogen Brain and Spine Institute
Locations: 1
Primary Endpoint: change in clinical symptoms over a period of 2 years
Status: Withdrawn
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Registry

clinicaltrials.gov

Start Date

August 2013

End Date

December 2018

Last Updated

7 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Neurogen Brain and Spine Institute

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•diagnosed cases of any type of Cerebral Palsy
•age above 6 months.

Exclusion Criteria

•presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/ Hepatitis C Virus
•malignancies
•bleeding tendencies
•pneumonia
•renal failure
•severe liver dysfunction
•severe anemia \[Hemoglobin \< 8\]
•any bone marrow disorder
•space occupying lesion in brain
•other acute medical conditions such as respiratory infection and pyrexia.

Outcomes

Primary Outcomes

change in clinical symptoms over a period of 2 years

Time Frame: 2 years

Clinical symptoms such as oromotor skills, sitting and standing balance, speech, ambulation, muscle tone, cognition, hand and leg movement, walking, etc